157 related articles for article (PubMed ID: 10557040)
1. Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies.
Corradini P; Ladetto M; Pileri A; Tarella C
Leukemia; 1999 Nov; 13(11):1691-5. PubMed ID: 10557040
[TBL] [Abstract][Full Text] [Related]
2. Molecular remission and non-Hodgkin's lymphoma.
Darby AJ; Johnson PW
Best Pract Res Clin Haematol; 2002 Sep; 15(3):549-62. PubMed ID: 12468405
[TBL] [Abstract][Full Text] [Related]
3. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.
Galimberti S; Marasca R; Caracciolo F; Fazzi R; Papineschi F; Benedetti E; Guerrini F; Morabito F; Oliva E; Di Renzo N; Federico M; Petrini M; Torelli G;
Bone Marrow Transplant; 2002 Apr; 29(7):581-7. PubMed ID: 11979307
[TBL] [Abstract][Full Text] [Related]
4. Significance of minimal residual disease in lymphoid malignancies.
Brüggemann M; Pott C; Ritgen M; Kneba M
Acta Haematol; 2004; 112(1-2):111-9. PubMed ID: 15179011
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
Chase ML; Armand P
Br J Haematol; 2018 Jan; 180(2):177-188. PubMed ID: 29076131
[TBL] [Abstract][Full Text] [Related]
6. Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD).
Olsson K; Gerard CJ; Zehnder J; Jones C; Ramanathan R; Reading C; Hanania EG
Leukemia; 1999 Nov; 13(11):1833-42. PubMed ID: 10557059
[TBL] [Abstract][Full Text] [Related]
7. [Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy].
Zhou A; Shi Y; Feng F; Lu S; He X; Han X
Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):467-70. PubMed ID: 12485501
[TBL] [Abstract][Full Text] [Related]
8. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
[TBL] [Abstract][Full Text] [Related]
9. Does MRD have a role in the management of iNHL?
Giudice ID; Starza ID; Foà R
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):320-330. PubMed ID: 34889425
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease in non-Hodgkin's lymphoma.
Schultze JL; Gribben JG
Biomed Pharmacother; 1996; 50(9):451-8. PubMed ID: 8991117
[TBL] [Abstract][Full Text] [Related]
11. Monitoring disease in lymphoma and CLL patients using molecular techniques.
Gribben JG
Best Pract Res Clin Haematol; 2002 Mar; 15(1):179-95. PubMed ID: 11987923
[TBL] [Abstract][Full Text] [Related]
12. Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA.
Garg S; Kumar A; Gupta R
Clin Transl Oncol; 2021 Nov; 23(11):2206-2219. PubMed ID: 33991328
[TBL] [Abstract][Full Text] [Related]
13. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.
Drandi D; Ferrero S; Ladetto M
Methods Mol Biol; 2018; 1768():229-256. PubMed ID: 29717447
[TBL] [Abstract][Full Text] [Related]
14. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
Chan DW; Liang R; Kwong YL; Chan V
Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
[TBL] [Abstract][Full Text] [Related]
15. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
[TBL] [Abstract][Full Text] [Related]
16. [Clinical importance of semi-quantitative monitoring of lymphomas using the comparative polymerase chain reaction].
Slavícková A; Ivánek R; Cerný J; Sálková J; Trnĕný M
Cas Lek Cesk; 2002 Nov; 141(23):735-8. PubMed ID: 12650030
[TBL] [Abstract][Full Text] [Related]
17. Detection and relevance of minimal disease in lymphomas.
Sharp JG; Chan WC
Cancer Metastasis Rev; 1999; 18(1):127-42. PubMed ID: 10505551
[TBL] [Abstract][Full Text] [Related]
18. The biological markers of non-Hodgkin's lymphomas: their role in diagnosis, prognostic assessment and therapeutic strategy.
Morra E
Int J Biol Markers; 1999; 14(3):149-53. PubMed ID: 10569136
[TBL] [Abstract][Full Text] [Related]
19. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis.
Shimoni A; Nagler A; Kaplinsky C; Reichart M; Avigdor A; Hardan I; Yeshurun M; Daniely M; Zilberstein Y; Amariglio N; Brok-Simoni F; Rechavi G; Trakhtenbrot L
Leukemia; 2002 Aug; 16(8):1413-8; discussion 1419-22. PubMed ID: 12145678
[TBL] [Abstract][Full Text] [Related]
20. Rearranged immunoglobulin light chain genes as minimal residual disease markers in intermediate- and high-grade malignant B cell non-Hodgkin's lymphoma.
Hoogeveen-Westerveld M; Hupkes PE; Doekharan D; Dorssers LC; van't Veer MB; van Belzen N
Leukemia; 1998 Nov; 12(11):1810-6. PubMed ID: 9823958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
